Contineum Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
33
- Stock Symbol
-
CTNM
- Share Price
-
$11.18
- (As of Friday Closing)
Contineum Therapeutics General Information
Description
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Contact Information
Website
www.contineum-tx.comCorporate Office
- 3565 General Atomics Court
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 3565 General Atomics Court
- Suite 200
- San Diego, CA 92121
- United States
Contineum Therapeutics Stock Performance
As of 24-Jan-2025, Contineum Therapeutics’s stock price is $11.18. Its current market cap is $288M with 25.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $11.18 | $11.28 | $11.08 - $22.00 | $288M | 25.8M | 98.2K | -$0.51 |
Contineum Therapeutics Financials Summary
As of 30-Sep-2024, Contineum Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 274,288 | |||
| Revenue | 0 | 50,000 | 0 | 0 |
| EBITDA | (43,570) | 18,967 | (24,297) | (28,421) |
| Net Income | (35,462) | 22,720 | (24,253) | (29,001) |
| Total Assets | 216,034 | 130,386 | 50,636 | 70,518 |
| Total Debt | 611 | 572 | 5,849 | 4,909 |
Contineum Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Contineum Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Contineum Therapeutics Comparisons
Industry
Financing
Details
Contineum Therapeutics Competitors (3)
One of Contineum Therapeutics’s 3 competitors is Oligomerix, a Venture Capital-Backed company based in White Plains, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oligomerix | Venture Capital-Backed | White Plains, NY | ||||
| Neurona Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| Ovid Therapeutics | Formerly VC-backed | New York, NY |
Contineum Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Contineum Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Contineum Therapeutics FAQs
-
When was Contineum Therapeutics founded?
Contineum Therapeutics was founded in 2017.
-
Where is Contineum Therapeutics headquartered?
Contineum Therapeutics is headquartered in San Diego, CA.
-
What is the size of Contineum Therapeutics?
Contineum Therapeutics has 33 total employees.
-
What industry is Contineum Therapeutics in?
Contineum Therapeutics’s primary industry is Drug Discovery.
-
Is Contineum Therapeutics a private or public company?
Contineum Therapeutics is a Public company.
-
What is Contineum Therapeutics’s stock symbol?
The ticker symbol for Contineum Therapeutics is CTNM.
-
What is the current stock price of Contineum Therapeutics?
As of 24-Jan-2025 the stock price of Contineum Therapeutics is $11.18.
-
What is the current market cap of Contineum Therapeutics?
The current market capitalization of Contineum Therapeutics is $288M.
-
Who are Contineum Therapeutics’s competitors?
Oligomerix, Neurona Therapeutics, and Ovid Therapeutics are competitors of Contineum Therapeutics.
-
What is Contineum Therapeutics’s annual earnings per share (EPS)?
Contineum Therapeutics’s EPS for 12 months was -$0.51.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
